Introduction {#s1}
============

Immune thrombocytopenia (ITP) is an acquired disorder characterized by a transient or persistent decrease in platelets accompanied with an increased risk of bleeding \[[@ref1],[@ref2],[@ref3]\]. The estimated incidence of ITP is 100 cases per 1 million people annually \[[@ref4]\]. Clinical presentation varies in a wide spectrum ranging from asymptomatic or mild cases with bruising and petechiae to severe mucocutaneous bleeding that could be life-threatening \[[@ref5],[@ref6]\]. Immune thrombocytopenia has been linked to an increased rate of immune-mediated platelet destruction; however, the exact pathophysiological mechanism is still unclear \[[@ref3]\].

In chronic ITP, antiplatelet antibodies facilitate platelet destruction and prevent the release of platelets from megakaryocytes, thus resulting in mild to serious thrombocytopenia. Therapeutic strategies for first- or second-line treatment such as corticosteroids, intravenous immunoglobulin, and splenectomy can reduce the destruction of antibody-coated platelets, but the efficacy is limited and serious adverse effects can be seen \[[@ref7]\]. Use of immunosuppressive drugs has been restricted because of serious adverse events and splenectomy has been linked to important drawbacks such as infection and thrombosis. Monitoring patients for the effectiveness of the treatment and for side effects is an important issue in the improvement of therapeutic outcomes.

Another treatment strategy is to use thrombopoietin receptor agonists (TPO-RAs) for stimulating platelet production through interaction with the TPO receptors present on megakaryocytes. One such example is eltrombopag, an oral, non-peptide thrombopoietin receptor agonist \[[@ref8]\]. Since eltrombopag does not compete with endogenous TPO binding at the extracellular TPO-R domain, it may possess an additive effect to thrombopoietin \[[@ref9]\]. As a consequence, the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway stimulates megakaryocytopoiesis, while autoantibody generation is not detected \[[@ref10]\]. Furthermore, eltrombopag does not influence agonist-induced platelet aggregation or activation \[[@ref1]\]. Eltrombopag produces a quick and sustainable increase in platelet counts and is generally well tolerated in patients with chronic ITP.

The present study aimed to analyze the outcomes of eltrombopag treatment in patients with chronic ITP in clinical practice in Turkey and to estimate the demographic, clinical, and hematological variables that may have implications for therapeutic response.

Materials and Methods {#s2}
=====================

Patients and Study Design {#s2a}
-------------------------

This retrospective study (2011-2017) was conducted in 55 tertiary care centers of Turkey. Data were collected from medical files of 285 chronic ITP patients, of whom 187 were women (65.6%) and 98 were men (34.4%). Patients with a diagnosis of chronic ITP according to the international consensus report \[[@ref11]\] irrespective of their age at diagnosis were eligible for inclusion if they received eltrombopag at any time in their treatment schedule. The exclusion criteria for treatment with eltrombopag consisted of HIV, hepatitis B, or hepatitis C infections; cardiovascular diseases; malignancy; chemotherapy or radiotherapy; prior diagnosis of myelodysplastic syndrome or aplastic anemia; and presence of two or more risk factors for thrombosis, such as smoking, diabetes mellitus, hypercholesterolemia, or hereditary thrombophilic disorders. Patients with a history of thrombosis were also excluded from the study because of the contraindication for these patients as a policy of the Ministry Health of Turkey.

The study was performed in accordance with the Declaration of Helsinki and conducted after the approval of the local institutional review board. Written informed consent was provided for all patients enrolled in this study. Chronic ITP is defined as persistent thrombocytopenia despite conventional initial management \[[@ref12]\]. Eltrombopag was administered at doses of 50 mg as a starting dose as approved by the Turkish Ministry of Health. After 2 weeks of treatment, if the platelet levels were \<30,000/µL, the dose was increased up to a maximal daily dose of 75 mg in increments of 25 mg. Achieving a platelet level between 150,000/µL and ≤250,000/µL, the daily dose was tapered by 25 mg. If platelet levels reached above 250,000/µL, eltrombopag was stopped, and after decreasing to \<100,000/µL the treatment was restarted by reducing the last daily dose by 25 mg. Descriptive data (age at diagnosis of chronic ITP, sex), therapeutic response (none, partial, or complete), side effects (absent or present), and severity of findings linked with bleeding (none, mild, moderate, severe, or life-threatening) were recorded. Platelet counts at first admission, before treatment, and at the 1^st^, 2^nd^, 3^rd^, 4^th^, and 8^th^ weeks; the number of days with platelet count of \>30,000/µL; maximum platelet counts after treatment; time to reach maximum platelet counts after treatment; and duration of follow-up were documented. Correlations between these descriptive, clinical, and hematological parameters were analyzed.

Severe or life-threatening bleeding was defined as either intracranial hemorrhage or bleeding that caused hemodynamic compromise and required intervention. Moderate bleeding was defined as bleeding that required blood transfusion but did not result in hemodynamic compromise. Minor bleeding was defined as bleeding that did not meet the criteria for either severe or moderate bleeding.

Response to treatment was defined as none (platelet count \<30,000/µL), partial (platelet count between 30,000/µL and 100,000/µL or platelet count double the initial value), or complete (platelet count \>100,000/µL).

Statistical Analysis {#s2b}
--------------------

Data were analyzed using IBM SPSS 20.0 software for Windows (IBM Corp., Armonk, NY, USA). The normal distribution of continuous variables was evaluated with the Kolmogorov-Smirnov test. Parametric tests were used for variables distributed normally, while non-parametric tests were utilized for variables without normal distribution. Correlation between variables was tested with Spearman's rho test. Categorical variables were compared with Pearson chi-square and Fisher exact tests, while two independent groups were compared using t-tests and Mann-Whitney U tests. Quantitative variables are demonstrated as mean ± standard deviation or median-interquartile range. The confidence interval was 95% and differences associated with a p-value of less than 0.05 were considered as statistically significant.

Results {#s3}
=======

The average age at diagnosis was 43.9±20.6 (range: 3 to 95) years. An outline of the demographic and clinical data of the present series is shown in [Table 1](#t1){ref-type="table"}. Before starting the eltrombopag treatment, clinical findings associated with bleeding were as follows: mild bleeding in 110 (38.6%) patients, moderate in 78 (27.4%), severe or life-threatening in 20 (7%), and no bleeding in 77 (27%). The numbers of chronic ITP patients with no response, partial response, or complete therapeutic response to eltrombopag treatment were 38 (13.4%), 65 (22.8%), and 182 (63.8%), respectively. Using a platelet level cut-off of \>30,000/µL, overall response rate was 86.7% (n=247). Considering patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and above 80 years old (n=12), overall response rate was 83% (n=10). The findings of the older patients above 60 and 80 years are listed in [Table 2](#t2){ref-type="table"}.

Platelet counts at first admission and before and after treatment (1^st^, 2^nd^, 3^rd^, 4^th^, and 8^th^ weeks) as well as maximum platelet count, number of days with platelet count \>30,000/µL, and interval (weeks) needed to achieve maximal platelet counts are presented in [Table 3](#t3){ref-type="table"}.

The median number of days required to achieve a platelet count of \>30,000/µL was 14 (range: 3-210). Median maximal platelet counts were 275,000-346,000/µL (range: 5150 to 2,068,000) and time interval until achievement of maximal platelet count was 8-18 weeks (range: 1-202).

Notably, there was a significant positive correlation between treatment response and number of days to achieve platelet count of \>30,000/µL (p=0.009, r=0.180). In contrast, age (p=0.129, r=0.764), platelet count at diagnosis (p=0.764, r=-0.020), and maximum platelet count after eltrombopag treatment (p=0.133, r=0.107) did not exhibit any correlation with treatment response.

Correlation analysis demonstrated that the higher the maximum platelet count was after eltrombopag treatment, the more likely side effects were to occur (p=0.004, r=0.215). [Table 4](#t4){ref-type="table"} demonstrates the results of correlation analysis seeking the association between clinical variables, platelet counts.

Sex (p=0.594) and age (≤40 years and \>40 years) (p=0.218) did not have a remarkable effect on treatment response. Similarly, platelet count at diagnosis did not seem to have a significant impact on treatment response (p=0.214).

Patients with platelet count of \>30,000/µL in the 1^st^, 2^nd^, 3^rd^, 4^th^, and 8^th^ weeks after eltrombopag treatment exhibited a better response to treatment (p\>0.001 for all). Pearson chi-square test results indicated that treatment response was similar among patients who had any degree of bleeding (p=0.089). Treatment response was statistically significantly associated with number of days with platelet count of \>30,000/µL (p=0.010), maximal platelet count (p\<0.001), and duration of follow-up (p\<0.001). On the contrary, treatment response was not affected by the week in which the highest platelet count was observed (p=0.121).

Our results demonstrated that the occurrence of side effects was not affected by sex (p=0.079), age (≤40 years and \>40 years) (p=0.079), or platelet count at diagnosis (p=0.586) or in the 1^st^ week (p=0.636), 2^nd^ week (p=0.761), 3^rd^ week (p=0.850), 4^th^ week (p=0.485), and 8^th^ week (p=0.527) after eltrombopag treatment. No association was noted between occurrence of side effects and number of days with platelet count of \>50,000/µL (p=0.206), the week in which maximal platelet count was achieved (p=0.231), or duration of follow-up (p=0.685).

Side effects were observed in 62 (21.8%) cases ([Table 1](#t1){ref-type="table"}). The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), venous thrombosis (4.2%), and arterial thrombosis (1.7%). Itching, erythromelalgia, transient ischemic attack, myalgia, and neuropathy were observed in 2 patients (3.9%) each.

The overall thrombosis rate including arterial (n=5) and venous thrombosis (n=12) was 5.9%. Thromboses presented clinically mostly as deep vein thrombosis. Pulmonary embolism was recorded in 3 patients. For arterial thrombosis, the main presentation was a transient ischemic attack (n=3). One patient suffered from ischemic stroke and one patient suffered from sudden death clinically attributed to a cardiac event. The thrombosis rate was found to be 2% in patients over 60 years of age and 16% in patients over 80 years of age. Clinical features and management of patients with thrombosis are summarized in [Table 5](#t5){ref-type="table"}.

Other side effects observed in only one patient each were as follows: hair loss, maculation, thrombocytosis, erythrocytosis, frequent tonsillitis, frequent pneumonia, diarrhea, and ileus. Side effects of any kind of grades 3-4, mainly thromboembolic events, were found at a rate of 6.3%.

Discussion {#s4}
==========

The present study was performed to investigate the variables that may be associated with treatment response and side effects after eltrombopag treatment for chronic ITP in daily practice. The overall response to eltrombopag in this cohort was 86.3%. This finding is consistent with previous prospective and retrospective studies \[[@ref13],[@ref14],[@ref15]\]. Our data have shown that platelet counts before, during, and after treatment as well as maximal platelet counts, duration of follow-up, and number of days to achieve platelet count of \>30,000/µL could have predictive potential for therapeutic response. Side effects were found to be significantly more common in patients with higher platelet counts after treatment. In our ITP cohort, the time to reach maximum platelet levels ​​during treatment with eltrombopag was quite variable (1-202 weeks). Platelet counts during different periods in the course of eltrombopag treatment for chronic ITP may possess important implications in terms of therapeutic response and side effect profile. In general, the response to treatment and side effects were similar in the elderly population, whereas thrombosis was more common in patients over 80 years of age, although the number of cases was small.

In chronic ITP, the goal of treatment is to provide sufficient platelet levels to avoid major bleeding and to minimize treatment-related toxicity. Patients with platelet counts of ≥30,000/µL are supposed to have adequate hemostasis and generally do not require treatment in the absence of a history of bleeding \[[@ref12]\]. Patients with ITP who have platelet counts above the normal minimum-maximum may have a risk of thrombotic or thromboembolic complications \[[@ref16]\]. Efforts must be made to improve functional capacity and maturation of platelets as well as platelet count to overcome bleeding problems in patients with chronic ITP while decreasing the side effects, especially serious thrombotic complications.

Our results suggest that platelet counts obtained at different intervals in the course of eltrombopag treatment can serve as important predictors for treatment response and occurrence of side effects. Patients with insufficient responses to treatments such as corticosteroids, immunoglobulins, or rituximab may also be appropriate candidates for eltrombopag treatment. Regular platelet counts and close follow-up are mandatory for monitoring the effectivity of treatment and potential safety issues.

Patients in eltrombopag clinical trials experienced both arterial and venous thrombosis. Of 135 patients receiving eltrombopag in the RAISE study, three (2.2%) developed venous thrombosis \[[@ref8]\]. The EXTEND extension study followed 299 patients for up to 5 years and reported nine patients with venous thrombosis and seven patients with arterial thrombosis (5.4%) \[[@ref17]\]. In the present study, venous thrombosis was observed in 12 patients (5.9%) and arterial thrombosis in 5 patients (1.7%). Although eltrombopag was generally well tolerated during treatment in RAISE, transient increases of alanine aminotransferase and indirect bilirubin concentrations were reported, perhaps related to the metabolism of both eltrombopag and bilirubin by UGT1A1 \[[@ref8]\]. All aminotransferase abnormalities were resolved; however, aminotransferase and bilirubin levels must be monitored before initiation of and during eltrombopag treatment, and treatment should be stopped if necessary. In the present study, none of the patients experienced increases in liver tests that required permanently discontinuing the drug. Of 135 patients in the RAISE study, 30% experienced headaches and 10% experienced fatigue, while in the present study, 4.2% of the study group reported headaches and 1.8% reported fatigue. The patient who died suddenly during follow-up had normal platelets at the last visit and the exact cause of death was clinically attributed to a cardiac event.

The main limitations of the current trial include the retrospective design, lack of a control group, and possible impacts of social, genetic, environmental, metabolic, and ethnic factors on treatment outcomes and side effects.

Conclusion {#s5}
==========

The results of the current study indicate that eltrombopag can be a safe and effective therapeutic option in refractory and chronic ITP, even in older populations. However, patients must be closely monitored for therapeutic response and side effects during treatment. Since both responses and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombosis risk factors.
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###### Descriptive and clinical data (n=285).
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###### Results of the older population.
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###### Data related to platelet count during the course of eltrombopag treatment.
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###### Correlations between clinical variables, platelet counts, treatment response, and side effects.
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###### Characteristic features of patients with thrombosis.
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